Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation Journal Article
| Authors: | Durie, B. G. M.; Kyle, R. A.; Belch, A.; Bensinger, W.; Blade, J.; Boccadoro, M.; Child, J. A.; Comenzo, R.; Djulbegovic, B.; Fantl, D.; Gahrton, G.; Harousseau, J. L.; Hungria, V.; Joshua, D.; Ludwig, H.; Mehta, J.; Morales, A. R.; Morgan, G.; Nouel, A.; Oken, M.; Powles, R.; Roodman, D.; San Miquel, J.; Shimizu, K.; Singhal, S.; Sirohi, B.; Sonneveld, P.; Tricot, G.; Van Ness, B. |
| Article Title: | Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation |
| Abstract: | These consensus guidelines have been compiled with input from the Scientific Advisors of the International Myeloma Foundation. Their production involved several steps including: • A 3-day Scientific Advisors meeting, during which each specific area was presented and discussed (May 2002). • Review of key literature, especially randomized study results, but also Medline, Internet, Cochrane database searches, and prior guidelines (Br J Haematol 115: 522-540, 2001). • Feedback from patients participating in the International Myeloma Foundation, patient programs. These guidelines encompass both the published literature and expert opinions. Recommendations based upon expert opinions are identified as such. The intent is for the guidelines to be international in scope, plus provide recommendations for both clinical practice and research approaches. 'Consensus' reflects general, although not necessarily unanimous, agreement. Details are discussed as appropriate. For convenience, the recommendations are divided into: 1 Diagnostic criteria. 2 Staging and prognostic factors. 3 Frontline therapy. 4 High-dose therapy and transplant. 5 Maintenance therapy. 6 Supportive care and management of specific complications. 7 Novel therapies and new technologies. |
| Keywords: | survival analysis; lenalidomide; prednisone; thalidomide; review; cisplatin; doxorubicin; dose response; drug efficacy; antineoplastic agents; cancer staging; nuclear magnetic resonance imaging; clinical practice; unindexed drug; consensus; bortezomib; multiple myeloma; nephrotoxicity; anemia; diagnosis, differential; etoposide; gastrointestinal symptom; antineoplastic combined chemotherapy protocols; maintenance therapy; internet; aciclovir; cyclophosphamide; dexamethasone; melphalan; steroid; vincristine; practice guideline; stem cell transplantation; diagnostic imaging; health program; arsenic trioxide; vincristine sulfate; quality assurance, health care; laboratory test; nonsteroid antiinflammatory agent; mitoxantrone; graft versus host reaction; muscle weakness; clinical research; medline; cataract; medical literature; methylprednisolone; skin disease; feedback system; clarithromycin; idarubicin; cochrane library; diagnostic test; cancer classification; vancomycin; sleep disorder; guidelines; irritability; management; recombinant erythropoietin; infection sensitivity; alendronic acid; mood disorder; myeloma; zoledronic acid; bone diseases; pamidronic acid; aminoglycoside; clodronic acid; attention deficit disorder; risedronic acid; kidney diseases; amphotericin b; body weight disorder; humans; prognosis; human; international myeloma foundation; 3 (4 amino 1,3 dihydro 1,3 dioxo 2h isoindol 2 yl)glutarimide |
| Journal Title: | Hematology Journal |
| Volume: | 4 |
| Issue: | 6 |
| ISSN: | 1466-4860 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2003-01-01 |
| Start Page: | 379 |
| End Page: | 398 |
| Language: | English |
| DOI: | 10.1038/sj.thj.6200312 |
| PUBMED: | 14671610 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 25 September 2014 -- Source: Scopus |
